FDA approves two Dako assays Dako, an Agilent Technologies company, announced it has received approval from the FDA for the addition of Kadcyla in the labeling of two Dako companion diagnostic assays. Kadcyla is Genentech's new medicine for patients with HER2-positive metastatic breast cancer who have received prior treatment with Genentech's cancer medicine Herceptin and a taxane chemotherapy. The two assays are Dako's HercepTest and HER2 IQFISH pharmDx.
Dako announces collaboration agreement with Amgen Dako, an Agilent Technologies (A) company, announced a new Master Collaboration Agreement with Amgen (AMGN). The expanded collaboration will allow both companies to benefit from knowledge-sharing within the field of drug-diagnostic research and development in general, and in relation to companion diagnostic products in particular. The financial details of the agreement were not disclosed.